Radiopharm Theranostics (ASX:RAD) has announced that the US FDA has granted Rare Pediatric Disease Designation for its DUNP19 technology for the treatment of osteosarcoma.
FDA grants important designation to Radiopharm Theranostics' DUNP19 technology
September 19, 2022 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Season 5, Episode 22
July 3, 2026 - - Podcast -
Is that a subtle but meaningful shift conceding the potential need for a response to global realities?
July 3, 2026 - -
New once weekly therapy offers extended protection for people with haemophilia A
July 3, 2026 - - Latest News -
Nothing else grows below this self-serving and broken institutional framework
July 3, 2026 - - Latest News -
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable
July 3, 2026 - - Latest News -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News

